Mikkel Bring Christensen

Mikkel Bring Christensen

Clinical Professor

Member of:

  • Clinical Pharmacology


  1. Published

    Cardiovascular effects of high-dose glucagon: a randomised clinical trial

    Petersen, K. M., Bogevig, S., Riis, T., Andersson, N. A. W., Dalhoff, Kim, Holst, Jens Juul, Knop, Filip Krag, Faber, Jens, Petersen, Tonny Studsgaard & Christensen, Mikkel Bring, 2020, In: Diabetologia. 63, SUPPL 1, p. S231-S231

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Published

    Clinical pharmacology of imeglimin for the treatment of type 2 diabetes

    Johansson, K. S., Brønden, A., Knop, Filip Krag & Christensen, Mikkel Bring, May 2020, In: Expert Opinion on Pharmacotherapy. 21, 8, p. 871-882

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

    Gasbjerg, Lærke Smidt, Bergmann, N. C., Stensen, S., Christensen, Mikkel Bring, Rosenkilde, Mette, Holst, Jens Juul, Nauck, M. & Knop, Filip Krag, 2020, In: Peptides. 125, 10 p., 170183.

    Research output: Contribution to journalReviewResearchpeer-review

  4. Published

    GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Gasbjerg, Lærke Smidt, Helsted, M. M., Hartmann, Bolette, wbf943, wbf943, Veedfald, Simon, Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, Mikkel Bring, Vilsbøll, Tina, Holst, Jens Juul, Rosenkilde, Mette & Knop, Filip Krag, 2020, In: Journal of Clinical Endocrinology and Metabolism. 105, 3, p. e725-e738 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications

    Stensen, S., Gasbjerg, Lærke Smidt, Helsted, M. M., Hartmann, Bolette, Christensen, Mikkel Bring & Knop, Filip Krag, 2020, In: Peptides. 125, 7 p., 170197.

    Research output: Contribution to journalReviewResearchpeer-review

  6. Published

    GIP infusion in patients with type 1 diabetes seems to attenuate post-prandial glucose excursions after prandial insulin over-dose and physical activity

    Hoe, B., Heimburger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Hartmann, Bolette, Holst, Jens Juul, Vilsbøll, Tina, Lund, A., Engberg, S., Dejgaard, T. F., Christensen, Mikkel Bring & Knop, Filip Krag, 2020, In: Diabetologia. 63, Suppl. 1, p. S117 1 p., 232.

    Research output: Contribution to journalConference abstract in journalResearch

  7. Published
  8. Published

    GIP's involvement in the pathophysiology of type 2 diabetes

    Christensen, Mikkel Bring, Gasbjerg, Lærke Smidt, Heimbürger, S. M., Stensen, S., Vilsbøll, Tina & Knop, Filip Krag, Mar 2020, In: Peptides. 125, 10 p., 170178.

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    GIP(3-30)NH2 – a tool for the study of GIP physiology

    Lynggaard, M. B., Gasbjerg, Lærke Smidt, Christensen, Mikkel Bring & Knop, Filip Krag, 2020, In: Current Opinion in Pharmacology. 55, p. 31-40 10 p.

    Research output: Contribution to journalReviewResearchpeer-review

  10. Published

    Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Jensen, M. E., Galli, A., Thomsen, M., Jensen, Kathrine Louise, Thomsen, G. K., Klausen, M. K., Vilsbøll, Tina, Christensen, Mikkel Bring, Holst, Jens Juul, Owens, A., Robertson, S., Daws, L., Zanella, D., Gether, Ulrik, Knudsen, Gitte Moos & Fink-Jensen, Anders, 2020, In: Neurochemistry International. 138, 9 p., 104772.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 Next

ID: 96275756